Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Healthtrust
Fuji
AstraZeneca
Colorcon
Teva

Generated: September 16, 2019

DrugPatentWatch Database Preview

Aprepitant - Generic Drug Details

  Try a free trial


See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for aprepitant and what is the scope of aprepitant freedom to operate?

Aprepitant is the generic ingredient in three branded drugs marketed by Glenmark Pharms Sa, Sandoz, Merck, Heron Theraps Inc, and Msd Merck Co, and is included in five NDAs. There are six patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Aprepitant has fifty-three patent family members in thirty-seven countries.

There are twenty-six drug master file entries for aprepitant. Five suppliers are listed for this compound.

US Patents and Regulatory Information for aprepitant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-002 Sep 24, 2012 AB RX No No   Try a Free Trial   Try a Free Trial   Try a Free Trial
Heron Theraps Inc CINVANTI aprepitant EMULSION;INTRAVENOUS 209296-001 Nov 9, 2017 RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Heron Theraps Inc CINVANTI aprepitant EMULSION;INTRAVENOUS 209296-001 Nov 9, 2017 RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for aprepitant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003   Try a Free Trial   Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003   Try a Free Trial   Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003   Try a Free Trial   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for aprepitant

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0748320 08C0019 France   Try a Free Trial PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
0734381 3/2004 Austria   Try a Free Trial PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
0734381 SPC/GB04/011 United Kingdom   Try a Free Trial PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
Harvard Business School
Chubb
Merck
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.